posted
Celluceutix Corporation (OTCBB CTIX): At Cellceutix, we have an exciting pipeline. We have the expertise of a large pharmaceutical company, but we're also focused, nimble and willing to supplement our own creative energies with ideas from the outside. We're focused on our lead candidate, Kevetrin, which we plan to develop for head and neck cancer. And we're focused on developing high quality data and patents to support Kevetrin. We're also open to new ideas from outside as well as inside. As a matter of fact, our pipeline already includes compounds licensed from the outside to supplement those invented by one of our co-founders, Dr. Krishna Menon. We're willing to partner with anyone who will help us meet our goals. When you put all this together, it means we at Cellceutix have a very exciting opportunity to create real value for our shareholders, as well as for our ultimate customers, the patients.
posted
Per their usual schedule, they should be about due for more news....................
Tue, Aug 25, 2009 7:30 AM Cellceutix Announces Acquisition of New Compound With High Blood Pressure Lowering Properties - GlobeNewswire Tue, Aug 18, 2009 5:32 AM Cellceutix Corp executes manufacturing agreement for Kevetrin API - M2 Presswire Mon, Aug 17, 2009 8:00 AM Cellceutix Signs Agreement for Kevetrin(tm) API - GlobeNewswire Wed, Jul 22, 2009 11:22 AM Stock Watch: CTIX, IFSL, LLFH - M2 Presswire 7:30 AM Cellceutix's Cancer Drug Shows No Significant Indications of Toxicity - GlobeNewswire Tue, Jul 14, 2009 5:41 PM Cellceutix Announces Dr. Samuel Danishefsky Joins Its Scientific Advisory Board - GlobeNewswire Mon, Jul 13, 2009 12:13 PM Stock Profiler.US: Stock Watch: BELM, MCII, CTIX - M2 Presswire 7:00 AM Cellceutix Announces Kevetrin(tm) Animal Model Testing Success Against Multi-Drug Resistant Lung Cancer Cell Lines - GlobeNewswire Tue, Jun 30, 2009 1:19 PM Stock Profiler.US: Stock Watch: ALKN, PGOG, CTIX - M2 Presswire 7:31 AM Cellceutix Announces Dr. Emil Frei to be On Its Scientific Advisory Board Through June 30, 2010 - GlobeNewswire Fri, May 22, 2009 7:21 AM Cellceutix Corp applies for cancer compound patent - M2 Presswire
posted
Forbes.com profile of Dr. Krishna Menon, CSO:
Krishna Menon President, Chief Scientific Officer and Director Cellceutix Corporation Beverly , MA Sector: HEALTHCARE / Biotechnology Officer since December 2007 61 Years Old Krishna Menon RCM, PhD, VMD served as President of Cellceutix Pharma since inception in June 2007. Following the acquisition, he was appointed President and a director. Dr. Menon, simultaneously therewith, also serves as the Chief Operating Officer at Kard Scientific, Inc. Dr. Menon is also the inventor of Kevetrin, our lead compound. Since June 2005, Dr. Menon is also the Chief Regulatory Officer (a non- executive officer position) at Nanoviricides, Inc. Dr. Menon has more than 35 years in drug development for academia and industry. Originally trained as a veterinary surgeon, Menon began his career as Chief Government Veterinarian for a major Parish in Jamaica. He segued to a three-year stint as Director of Agriculture for the Cayman Islands, in the British Caribbean and, in 1982, moved to the Dana Farber Cancer Research Institute, where he worked under the direction of Nobel Laureate Dr. Tom Frye. Two years later, he earned his PhD in Pharmacology from Harvard University. Menon's PhD work focused on anti-folate therapy of various cancers. Menon was Research Scientist at Dana Farber from 1985 to 1990 and Senior Research Scientist, In Vivo Research (Cancer), at Bayer Pharmaceuticals (Miles Laboratories) from 1991 to 1993. After a year operating his own veterinary oncology and drug development consultancy practice, Menon was tapped Group Leader, Cancer In Vivo Research and Clinical Development, for Eli Lilly (1995-2001), where he played a key role in lead selection and pre-clinical development of Gemzar and Alimta which in 2006 had over 2.1 billion dollars ($2,100,000,000) in sales, and co-developed another seven compounds currently in late-stage clinical development. In 1999, Lilly honored Menon as "Employee of the Year." Lilly's is one of the few "Employee of the Year" awards not bestowed annually but, rather, on only special occasions. .
IP: Logged |
posted
Dr. Krishna Menon, President, Chief Scientific Officer and Director Cellceutix Corporation Beverly , MA Sector: HEALTHCARE / Biotechnology Officer since December 2007
Krishna Menon RCM, PhD, VMD served as President of Cellceutix Pharma since inception in June 2007. Following the acquisition, he was appointed President and a director. Dr. Menon, simultaneously therewith, also serves as the Chief Operating Officer at Kard Scientific, Inc. Dr. Menon is also the inventor of Kevetrin, our lead compound. Since June 2005, Dr. Menon is also the Chief Regulatory Officer (a non- executive officer position) at Nanoviricides, Inc. Dr. Menon has more than 35 years in drug development for academia and industry. Originally trained as a veterinary surgeon, Menon began his career as Chief Government Veterinarian for a major Parish in Jamaica. He segued to a three-year stint as Director of Agriculture for the Cayman Islands, in the British Caribbean and, in 1982, moved to the Dana Farber Cancer Research Institute, where he worked under the direction of Nobel Laureate Dr. Tom Frye. Two years later, he earned his PhD in Pharmacology from Harvard University. Menon's PhD work focused on anti-folate therapy of various cancers. Menon was Research Scientist at Dana Farber from 1985 to 1990 and Senior Research Scientist, In Vivo Research (Cancer), at Bayer Pharmaceuticals (Miles Laboratories) from 1991 to 1993. After a year operating his own veterinary oncology and drug development consultancy practice, Menon was tapped Group Leader, Cancer In Vivo Research and Clinical Development, for Eli Lilly (1995-2001), where he played a key role in lead selection and pre-clinical development of Gemzar and Alimta which in 2006 had over 2.1 billion dollars ($2,100,000,000) in sales, and co-developed another seven compounds currently in late-stage clinical development. In 1999, Lilly honored Menon as "Employee of the Year." Lilly's is one of the few "Employee of the Year" awards not bestowed annually but, rather, on only special occasions.
Excellent results in animal model experiments in drug-resistant cancers Kevetrin, our lead product candidate, is a small molecule compound proprietary to the Company. Its structure is distinct from other anti-cancer agents currently on the market. Kevetrin was discovered by the Company's founder, Dr. Krishna Menon, and has been studied extensively (in vitro and in vivo) demonstrating potent anti-cancer activity against various cancer cell lines. Kevetrin's recent success in a series of animal model experiments with drug-resistant cancer cell lines, has galvanized the Company to focus on Kevetrin's development potential in this area. Kevetrin's primary mechanism of action is as an AKT inhibitor but it also acts as an alkylating agent and LTB4 inhibitor with anti-angiogenic properties. Some highlights of the studies conducted to date include:
* Small molecule drug that is structurally different from anti-cancer agents currently on the market * Primary mechanism of action is AKT inhibition * Potent in vitro cytotoxicity against a panel of human tumor cell lines * Demonstrated success in more than 5,000 small animal tests, achieving significant delays in tumor growth compared to controls in breast, prostate and colon cancer tumors. * In animal tests of a head and neck cancer cell line, delay in tumor growth was significantly increased by 14 days with Kevetrin alone (about the same as with radiation alone) but when Kevetrin was administered in conjunction with radiation, tumor growth delay increased by 36 days, more than two-fold compared to controls * In small animal tests, Kevetrin was well tolerated. We are now conducting additional studies to allow us to request permission from FDA to begin studies in humans.
posted
CTIX is starting to get some trading activity now and the Bid-Ask has tightened up. Perhaps some good news in on the way. Their website says they are looking to go to initial FDA trials. .
IP: Logged |
posted
NEWS: Cellceutix Meets With One of the World's Largest Pharmaceutical Companies At Partnering Meeting Sep. 23, 2009 (GlobeNewswire) --
BEVERLY, Mass., Sept. 23, 2009 (GLOBE NEWSWIRE) -- Cellceutix Corporation (OTCBB:CTIX), an emerging bio-pharmaceutical company in the business of developing small-molecule therapies in areas of unmet medical needs, announced today that its officers met with one of the world's largest pharmaceutical companies at the pharma's partnering meeting last week. Cellceutix was invited to introduce its anti-inflammatory drug pipeline in "face to face" meetings with the business development staff of this major pharmaceutical company, whose name was not disclosed. The pharmaceutical company is seeking the best advances in modern medicine to strengthen its R&D portfolio.
"We were taken by surprise to have received this prestigious invitation considering we have released very little information about these specific compounds. To have received this invite is testament to the quality of Cellceutix's compound pipeline and the supporting science," said Leo Ehrlich, chief financial officer of Cellceutix. "As we move the compounds along in development, we will continue to communicate with this pharmaceutical company as well as others. Currently we are expending an enormous effort on Kevetrin, our lead oncology compound, which has consistently shown success in animal models against drug resistant cancers. Of our compounds, this drug is furthest along in preclinical development and we hope to progress it rapidly through Phase 1 clinical studies."
About Cellceutix Corp.:
Headquartered in Beverly, Mass., Cellceutix is an emerging bio-pharmaceutical company in the business of developing small-molecule therapies in areas of unmet medical needs. It owns the rights to seven drug compounds, including Kevetrin, which it is developing as a treatment for certain cancers, and KM-133, which it is developing for psoriasis. For more information, visit: www.cellceutix.com.
This release contains forward-looking statements with respect to the results of operations and business of Cellceutix Corporation, which involve risks and uncertainties. The Company's actual future results could materially differ from those discussed. The Company intends that such statements about the Company's future expectations, including future revenues and earnings, and all other forward-looking statements, be subject to the "Safe Harbors" provision of the Private Securities Litigation Reform Act of 1995.
All forward-looking statements are also expressly qualified in their entirety by the cautionary statements included in Cellceutix's SEC filings, including its quarterly reports on Form 10-Q and its annual report on Form 10-K. Positive results in animal studies do not necessarily predict success in human trials.
CONTACT: The Mishra Group, Inc. Upendra Mishra (781) 466-9900, ext. 215 Umishra*MishraGroup.com
posted
“Pharmaceutical Micro-Cap Company Demonstrates Significant Delay of Tumor Growth in Drug Resistant Breast Cancer.”
Companies mentioned in this article include Cellceutix Corporation (OTCBB: CTIX).
Article Excerpt:
It is the scourge of our era, and that era’s women. More than 1.3 million women worldwide are diagnosed with breast cancer annually, and more than a third of these (465,000) will lose their battle with the deadly disease. About 41,000 of these deaths will be in the United States, according to the latest figures from the American Cancer Society.
The cry for a treatment, a cure - to be more optimistic, a preventive measure – is growing louder day by day, for these numbers are tragically high. Fortunately, the cry is being heard in several quarters of the medical community, provoking cheers of delight from patients, their doctors, and small cap investors.
On the last official, full day of summer came word from Cellceutix Corporation (OTCBB: CTIX), a Massachusetts-based researcher, that successful tests had been completed on animals involving the company’s pharmaceutical compound known as Kevetrin™. The tests were performed on a taxane-resistant, estrogen receptor-negative breast cancer human cell line, MDA-MB-435s, and compared favorably with other cancer fighters such as paclitaxel and cisplaten in delaying tumor growth.
**************.com is focused on the small-cap / penny stock market and has become a reputable name in the investment community. **************.com runs a Canadian and US site to provide investors in Canada as well as the United States with informative and unique content and information. **************.com runs weekly stocks to watch, has a daily market write-up, provides company spotlights, runs unique most active pages strictly for penny stocks trading on the TSX, TSX Venture, NASDAQ and OTC BB, and much more information for the average investor.
**************.com also runs an email newsletter that aims to uncover stocks that are still under the radar of most investors. Criteria **************.com looks for includes strong revenues, a seasoned management, innovative business plans, among many others. **************.com also looks for companies that announce breaking news, recent 52-week highs/lows, technical breakouts, and other favorable corporate information.
Investors are encouraged to subscribe to the **************.com FREE e-mail newsletter and see what tens of thousands of other investors have already been receiving since 1999. Investors can receive their free newsletter subscription by clicking here: http://www.**************.com/aps_common/newsletter_free.asp.
Tue, Oct 06, 2009 8:15 AM A New Audio Interview with Cellceutix Corporation's CEO, George Evans, is Now at SmallCapVoice.com - Business Wire 3:57 AM Opinions Requested on Proprietary Compound Successfully Tested: Review Initiated by Online Financial Magazine and Investor Social Network - M2 Presswire Mon, Oct 05, 2009 8:17 PM AXcess News: Breast Cancer Awareness Draws Investors Too - Marketwire 4:01 PM Cellceutix Compound Shows Significant Effect On Psoriasis - GlobeNewswire .
IP: Logged |
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
